

**Starting Clinical Trials: The 70- day benchmark**  
**1<sup>st</sup> April 2015 – 30<sup>th</sup> June 2015**

REC Reference	Trial	Date of valid document set receipt	Date of NHS Permission	Date of first recruit	Benchmark Met	Reasons for not achieving the 70 day benchmark
13/WM/0419	Mammo 50	14/07/2014	15/07/2014	29/08/2014	Yes	
13/WA/0184	AML-19	13/08/2014	08/09/2014		No	Sponsor Delay: Issues with trial centre not having the drug supply/ contract in place nationally.
13/NS/0143	The SIMS Trial	04/09/2014	17/09/2014	05/12/2014	No	Sponsor Delay: Delay in CI completing learning curve in theatres with PI and then PI on annual leave cause delay. Site physically opened to recruitment 03/11/2014.
14/SC/1014	The JANUS 1 Study Incyte INCB 18424362	19/09/2014	10/10/2014	10/03/2015	No	Sponsor Delay: Study not open to recruitment, awaiting sponsors approval on the test images before our site can be activated. Rare disease.
13/SC/0379	RESPIRE (CARD 3360)	22/09/2014	15/10/2014	19/03/2015	No	Sponsor Delay: Elective pacing temporarily suspended between December 2014 and March 2015. First patient recruited 19/03/2015.
14/EM/1005	CCRN 3204- Phase 3 Masitinib /Placebo + Docetaxel in Metastatic Prostate Cancer V1 AB12003	25/09/2014	15/10/2014	10/03/2015	No	Sponsor Delay: IMP delay from sponsor.
14/WM/0166	Assessing QbTest Utility in ADHD: A Randomised Controlled Trial	26/09/2014	16/10/2014	18/11/2014	Yes	
11/WM/0287	DESKTOP III - A randomized multicentre study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer	02/10/2014	23/10/2014	17/02/2015	No	Sponsor Delay: Letter received from the trial centre stating our site numbers and that we are open for recruitment from 11/11/2014. End of recruitment originally advised as 01/02/2015 by sponsor. Later advised study had been extended. No patients were eligible in the interim between 11/11/2014 and 01/02/2015. Once confirmed study extended eligible patient identified 17/02/2015.

14/YH0085	FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab	13/11/2014	20/11/2014	19/05/2015	No	Sponsor Delay: Pharmacy green light 22/12/2014, drug delivered by the sponsor on 15 December and the sponsor initiated the site on 22 December, study now open to recruitment. rare condition. No eligible patients prior to first recruit.
13/WA/0205	AML-18	08/01/2015	12/01/2015	17/06/2015	No	Pharmacy Green Light 05/02/2015. There weren't any eligible patients identified during initial screening. This is not a common cancer so no eligible patients identified until 17/06/2015.
12/WM/0187	ROCSS Reinforcement of closure of stoma site	26/01/2015	05/02/2015	06/03/2015	Yes	
13/SC/0111	FOCUS4: Molecular selection of therapy in colorectal cancer	06/02/2015	25/02/2015		No	Sponsor Delay: Site Activation approval given 14/05/2015. No eligible patients to date from screenings.
12/NE/0401	Folic Acid Clinical Trial (FACT)	23/02/2015	09/03/2015	01/06/2015	No	Sponsor Delay: Site Activation approval given 29/04/15. 1st recruit 01/06/15. 33 days to FPI from site activation.
14/LO/2011	CCRN 2833 DUAL antithrombotic therapy with dabigatran etexilate (RE-DUAL PCI)	13/03/2015	18/03/2015	27/04/2015	Yes	Site Activation approval given 28/04/2015
14/SC/1219	Airways Management in Cardiac Arrest patients - Airways-2	16/04/2015	08/05/2015	13/07/2015	No	Difficult to recruit patients due to low survival rate. EMAS perform randomisation.
14/NE/007	Computer Game for Rehab Young People	11/06/2015	25/06/2015		Within 70 days	Within 70 days
14/WM/1055	NCRN 3246 Masitinib/Placebo + FOLFIRI in Metastatic Colorectal Cancer V1.1 AB12006	20/04/2015	27/04/2015		No	Sponsor Delay: Pharmacy green light given from 23/07/2015. Delays from sponsor on Pharmacy queries.
12/LO/1078	MUK five	25/06/2015	26/06/2015	21/07/2015	Yes	
13/YH/0229	GO2	24/03/2015	13/04/2015		No	Sponsor Delay: Request from Sponsor to add additional arms after approval.